Acquired byMitsubishi Tanabe Pharma Corporation on Jul, 2017;
?
Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
NeuroDerm
NeuroDerm Overview
NeuroDerm specializes in integrating proprietary pharmaceutical formulations, state-of-the-art delivery system, and digital health solutions with the aim of reducing disease burden and improving the quality of life of patients and their families.
NeuroDerm’s flagship product ND0612 is currently in late stage development for Parkinson’s disease patients experiencing motor fluctuations. Its system for self-administered continuous subcutaneous infusion of the gold standard levodopa/carbidopa, was designed specifically to be a user-friendly system for people with Parkinson's disease, to maintain steady therapeutic levodopa plasma concentrations for the purpose of improving fluctuations, that is, reducing patients’ "OFF" time without increasing troublesome dyskinesia.
Its tailored solution potentially offers sustained relief (compared to oral immediate-release levodopa/carbidopa treatments) and empowers patients and their families to regain control of their lives with greater daily-life predictability and independence.
NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations
undefined
Aug 28, 2019
www.prnewswire.com
Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations
#Customers
Jul 24, 2017
globenewswire.com
NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash
NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations
undefined
Aug 28, 2019
www.prnewswire.com
Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations
#Customers
Jul 24, 2017
globenewswire.com
NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash
#Acquisition
Jun 13, 2017
www.globes.co.il
Neuroderm mulls several acquisition offers
#Acquisition
Mar 2, 2017
www.globes.co.il
Neuroderm jumps on successful trial results
#Customers
View other companies you might be interested in
NeuroDerm Team
No Data, yet.
Sorry, no content found under this section.
View other companies you might be interested in
Connect with
What is the reason for connecting? *
Your company *
Company website (recommended)
Please enter a valid website
Your organization type *
Please enter a valid organization type
Your position *
Add invitation message
0/300
Sending invitation...
Invitation sent
You will be able to start a conversation once [Name] accepts it.